last
decad
wit
enorm
chang
understand
allerg
rhiniti
begun
unravel
complex
underli
immunolog
inflammatori
pathophysiolog
diseas
new
therapeut
strategi
well
specif
molecular
cellular
constitu
emerg
potenti
target
clinic
intervent
effort
also
shed
light
mechan
current
antiallergi
medic
actor
sometim
fail
effet
similar
pathophysiolog
basi
allerg
rhiniti
often
comorbid
condit
asthma
underscor
recent
publish
american
thorac
societi
workshop
summari
immunobiolog
asthma
rhiniti
pathogen
factor
therapeut
conclus
workshop
chair
thoma
counsel
reader
consid
allerg
asthma
rhiniti
repres
system
diseas
affect
two
organ
lung
nose
asthma
allerg
rhiniti
share
mani
pathogen
factor
oper
differ
part
airway
inflammatori
cell
mediat
often
may
common
alter
occur
immun
system
thu
therapeut
strategi
potenti
therapeut
agent
found
benefici
treatment
one
airway
target
may
show
similar
effect
reason
mani
therapi
develop
earli
stage
evolut
physician
interest
rhiniti
therapi
also
must
examin
known
agent
asthma
one
avenu
activ
research
role
leukotrien
mediat
pathophysiolog
asthma
rhiniti
three
leukotrien
modifi
approv
treatment
asthma
unit
state
potenti
use
treatment
rhiniti
focu
consider
specul
investig
earli
day
p
r
k
studi
show
antileukotrien
therapi
patient
rhiniti
demonstr
improv
rhinit
p
roquet
et
report
treatment
asthma
j
e
r
e
synergist
effect
antileukotrien
agent
antihistamin
use
compar
either
drug
alon
product
combin
antileukotrien
antihistamin
current
develop
excit
develop
howev
may
immunolarena
describ
baraniuk
elsewher
issu
pathop
ysiolog
allerg
rhiniti
highli
complex
multipl
interact
interdepend
redund
pathway
molecular
cellular
constitu
involv
pathogenesi
allerg
rhiniti
briefli
exposur
nasal
mucosa
allergen
sensit
individu
lead
releas
product
inflammatori
mediat
releas
cytkin
releas
cytokin
activ
endotheli
cell
therebi
induc
express
adhes
receptor
cell
surfac
initi
cascad
event
facilit
transendotheli
migrat
inflammatori
cell
lymphocyt
also
activ
cytokin
within
given
tissu
specif
pattern
cytokin
releas
depend
domin
subset
local
lymphocyt
turn
lead
preferenti
activ
recruit
specif
inflammatori
cell
characterist
cellular
inflamm
observ
allerg
rhiniti
cytokin
potent
biolog
factor
pleiotrop
redund
synergist
function
everi
nucleat
cell
may
releas
cytokin
given
cytokin
may
multipl
cell
sourc
cytokin
predominantli
act
short
distanc
singl
cytokin
singl
cell
type
sole
respons
variou
event
inflammatori
respons
evid
complex
network
interconnect
process
requir
gener
event
clinic
recogn
allerg
inflammatin
improv
understand
immunolog
underpin
allergi
provid
new
opportun
therapeut
intervent
basi
immun
function
heterogen
abil
lymphocyt
respons
protein
antigen
microb
allergen
tumor
cell
differenti
subset
effector
cell
produc
distinct
set
elicit
distinct
effector
function
fig
l
thu
specif
popul
helper
lymphocyt
th
distinguish
basi
secret
cytokin
accord
paradigm
mosmann
et
undifferenti
naiv
helper
cell
tho
cell
appropri
condit
may
differenti
along
distinct
pathway
becom
either
lymphocyt
pathway
follow
determin
type
stimul
especi
local
cellular
cytokin
milieu
produc
time
antigen
recognit
major
function
differenti
cell
regul
cellmedi
defens
tumor
cell
infect
particularli
defens
viral
fungal
mycobacteri
intracellular
pathogen
signific
cytokin
elabor
differenti
cell
interferoni
ifni
cytokin
stimul
microbicid
activ
phagocyt
increas
class
major
histocompat
complex
mhc
molecul
express
activ
neutrophil
stimul
cytolyt
activ
natur
killer
nk
cell
activ
vascular
endotheli
cell
therebi
promot
lymphocyt
adhes
extravas
importantli
ifni
promot
tcell
differenti
h
subtyp
inhibit
differenti
cell
promot
domin
thu
net
effect
ifni
product
promot
macrophagerich
inflammatori
reaction
inhibit
igedepend
eosinophilmedi
reaction
cell
also
produc
cytokin
known
stimul
prolifer
differenti
cell
aid
develop
cytotox
lymphocyt
ctl
produc
tion
lymphotoxin
lt
promot
recruit
activ
neutrophil
endotheli
cell
convers
cell
subtyp
seem
function
physiolog
regul
immun
respons
inhibit
potenti
damag
respons
major
cytokin
produc
activ
cell
mediat
allerg
reaction
defens
helminth
infect
illo
antagon
action
ifni
therebi
suppress
macrophag
activ
stimul
differenti
antigenstimul
cell
subset
l
lead
interest
conundrum
differenti
cell
major
sourc
yet
cytokin
obligatori
differenti
current
think
suggest
antigenstimul
cell
includ
nkt
cell
cell
mast
cell
secret
small
quantiti
context
persist
antigen
stimul
concentr
local
increas
inflamm
trigger
product
result
increas
differenti
subset
thu
socal
key
determin
profil
may
persist
repeat
tcell
stimul
littl
inflamm
macrophag
activ
possibl
explan
includ
product
cell
type
genet
factor
influenc
individu
sensit
excess
uncontrol
prolifer
associ
defici
cellmedi
immun
particularli
infect
intracellular
microb
eg
mycobacteria
support
conceptu
model
allerg
inflamm
found
sever
experiment
observ
vivo
studi
linden
et
challeng
allerg
rhiniti
subject
birch
pollen
normal
subject
coronaviru
ten
normal
subject
inocul
develop
upper
respiratori
infect
uri
contrast
patient
allerg
rhiniti
subject
develop
uri
increas
level
ifni
p
nasal
lavag
fluid
correl
symptom
p
author
clearli
show
distinct
cytokin
profil
express
viral
uri
allerg
rhiniti
therebi
support
concept
cytokin
especi
ifni
present
viral
infect
schwartz
et
measur
tcell
cytokin
respons
ifni
two
adult
patient
mildli
atop
extrem
elev
ige
level
iu
ml
compar
cell
obtain
control
subject
peripher
blood
monocyt
obtain
patient
cultur
presenc
ifni
refractori
stimuli
tetanu
phytohemaglutinin
author
conclud
elev
ige
level
repres
overli
domin
tcell
commit
cytokin
pattern
specul
patient
may
defect
regul
taverni
et
attempt
discern
whether
differ
atop
nonatop
individu
result
prolif
respons
stimul
cell
cytokin
profil
elicit
cell
peripher
blood
mononuclear
cell
atop
nonatop
subject
stimul
vitro
hous
dust
mite
cat
dog
allergen
cell
cultur
supernat
assay
ifni
differ
either
tcell
prolifer
ifni
level
detect
atop
versu
nonatop
subject
significantli
higher
level
howev
detect
among
mitesensit
subject
stimul
mite
extract
catsensit
subject
stimul
cat
extract
similarli
level
significantli
higher
among
catsensit
subject
stimul
cat
extract
dogsensit
atop
subject
stimul
dog
extract
result
point
differ
elicit
cytokin
profil
stimul
cell
rather
differ
abil
prolifer
respons
allergen
stimul
suggest
respiratori
tract
infect
earli
childhood
may
confer
protect
allerg
sensitizationzz
underli
mechan
protect
believ
involv
stimul
immun
respons
upregul
cytokin
ie
ifni
context
earli
infect
would
expect
dampen
effect
differenti
cell
yabuhara
show
atop
subject
least
respect
inhal
allergen
hous
dust
mite
polar
probabl
establish
infanc
earli
childhood
time
subject
reach
year
age
atop
cytokin
profil
becom
evid
support
come
find
children
lower
respiratori
infect
without
wheez
lower
level
ige
compar
wheez
episod
higher
level
ifni
result
suggest
lack
ifni
may
predispos
ige
view
support
recent
investig
document
significantli
elev
ige
level
time
first
wheez
episod
subject
went
develop
persist
wheez
symptom
rel
level
found
patient
wheez
nonatop
patient
wheez
similar
relationship
infect
atopi
found
popul
studi
among
japanes
tuberculosi
west
african
measl
case
result
prompt
investig
specul
tip
balanc
toward
respons
earli
infect
may
confer
protect
develop
atopi
also
may
explain
greater
preval
atopi
allerg
disord
among
singl
older
children
among
younger
sibl
among
young
children
daycar
state
anoth
way
improv
control
infecti
diseas
tuberculosi
may
help
explain
recent
rise
preval
allergi
asthma
mani
countri
worldwid
convers
et
report
patient
multipl
sclerosisa
diseas
character
excess
product
cytokineshad
significantli
lower
rate
allerg
symptom
lower
number
allergenspecif
ige
test
result
lower
composit
allergi
indic
control
subject
find
serv
valid
critic
role
balanc
develop
atopi
earli
becom
appar
specif
cytokin
influenc
subsequ
develop
thelper
cell
subsetsn
later
investig
analyz
pattern
cytokin
product
splenic
thelper
cell
mice
found
cultur
undifferenti
thelper
cell
presenc
monoclon
antibodi
mab
yield
two
distinct
popul
cell
th
cell
cultur
presenc
differenti
cell
character
product
cultur
presenc
mab
develop
cell
character
product
undifferenti
h
precursor
tho
cell
secret
author
postul
lead
downregul
ifni
favor
develop
precursor
cell
furthermor
presenc
establish
posit
feedback
downregul
product
inhibit
therebi
prevent
tho
cell
develop
cell
thu
act
inhibit
differenti
promot
differenti
necessari
signal
latter
interestingli
select
growth
effect
cell
matur
acquir
pattern
cytokin
product
remain
stabl
longer
influenc
presenc
absenc
context
asthmat
inflamm
also
seem
crucial
recruit
cell
migrat
eosinophil
lung
tissu
airway
addit
role
tlymphocyt
differenti
cellmedi
immun
respons
critic
role
humor
immun
respons
well
establish
box
also
known
bcell
stimulatori
factor
cytokin
respons
regul
switch
immunoglobulin
heavi
chain
isotyp
product
iggl
ige
b
lymphocyt
fig
central
role
isotop
switch
support
fact
il
defici
knockout
mice
produc
serum
ige
therefor
impair
defens
helminth
parasit
develop
immedi
hypersensit
ie
allerg
reason
becam
earli
focu
investig
role
cytokin
allerg
respons
finkelman
et
show
critic
gener
susten
ige
respons
vivo
demonstr
earli
administr
larg
quantiti
monoclon
antibodi
capabl
inhibit
ige
respons
monoclon
antibodi
given
peak
respons
declin
serum
ige
hasten
base
observ
author
specul
regul
product
activ
may
appropri
therapeut
target
allerg
disord
subsequ
studi
mous
model
human
corrobor
expand
observ
numer
investig
attempt
discern
mechan
molecular
interrelationship
underli
event
antigenspecif
tb
cell
interact
releas
cell
bind
receptor
b
cell
result
isotyp
switch
ige
product
bind
receptor
rest
b
lymphocyt
also
induc
express
anoth
cell
surfac
molecul
lowaffin
ige
postul
involv
regul
ige
product
fccri
highaffin
ige
receptor
express
surfac
mast
cell
basophil
also
increas
bind
antigen
ige
molecul
effector
cell
subsequ
crosslink
cellbound
ige
trigger
degranul
mediat
releas
ifn
strongli
inhibit
induct
well
ige
prodction
context
allerg
inflamm
sever
effect
fig
directli
upregul
express
vascular
cell
adhes
surfac
vascular
endotheli
cell
select
promot
eosinophil
adhes
migrat
one
report
suggest
express
highaffin
receptor
human
lung
fibroblast
may
recruit
activ
cell
therebi
induc
airway
remodel
characterist
asthma
associ
higher
level
express
enhanc
signal
among
popul
adult
allel
found
subject
atopi
five
nonatop
subject
p
moreov
three
three
patient
hyperig
syndrom
four
seven
patient
sever
atop
dermat
carri
mutat
accord
author
mutat
inherit
classic
mendelian
fashion
appear
widespread
suggest
may
contribut
pathogenesi
varieti
allerg
diseas
major
subject
identifi
carri
singl
copi
mutant
allel
found
atopi
suggest
domin
effect
howev
carrier
includ
one
homozyg
mutat
atop
thu
factor
may
involv
eg
separ
genet
loci
impart
suscept
protect
atopi
environment
factor
exposur
allergen
recent
publish
abstract
describ
relationship
polymorph
promotor
region
asthma
sever
investig
report
among
white
presenc
allel
associ
asthma
greater
sever
determin
percent
predict
forc
expiratori
volum
one
second
fev
therebi
provid
first
evid
associ
asthma
sever
specif
genet
locu
asthma
severityassoci
allel
subsequ
found
investig
present
much
higher
frequenc
black
suggest
allel
may
help
explain
increas
preval
sever
asthma
among
black
pillari
et
al
similarli
describ
specif
mutat
subunit
associ
asthma
among
black
accord
find
clinic
observ
patient
asthma
shown
elev
cell
bronchoalveolar
nasal
induc
immunohistochem
stain
inferior
turbin
biopsi
patient
allerg
rhiniti
control
nonatop
subject
also
establish
presenc
significantli
patient
virtu
pleiotrop
effect
pivot
role
develop
allerg
inflamm
becom
prime
therapeut
target
current
least
four
distinct
strategi
modul
effect
explor
box
clinic
trial
use
one
approach
alreadi
commenc
nearli
decad
ago
maliszewski
et
ala
abl
show
recombin
solubl
receptor
clone
extracellular
portion
mous
human
receptor
could
use
inhibit
bcell
activ
vitro
solubl
receptor
act
decoy
bind
inactiv
could
bind
cellsurfacebound
receptor
prevent
subsequ
signal
fig
solubl
receptor
inhibit
ilmepend
bcell
differenti
therebi
abrog
isotyp
switch
function
induc
ige
iggl
product
subscquent
vivo
studi
show
antagon
function
mediat
endogen
eg
ige
secret
delin
time
cours
relev
respons
found
effect
inhibit
earli
stage
igebcel
renz
et
demonstr
intraperiton
inject
significantli
suppress
ige
iggl
antibodi
product
cutan
hypersensit
respons
sensit
mice
airway
respons
also
decreas
effect
similar
produc
intraperiton
inject
monoclon
antibodi
interestingli
deliveri
way
airway
nebul
prove
potent
modul
airway
hyperrespons
also
effect
inhibit
hypersensit
responseslead
author
specul
solubl
receptor
may
effect
therapi
allerg
respons
aerosol
allergen
studi
use
intraperiton
intranas
allergenchalleng
mous
model
asthma
recent
complet
anticip
aerosol
deliveri
solubl
receptor
effect
block
aspect
latephas
pulmonari
respons
person
commun
w
henderson
may
result
two
studi
indic
effect
given
base
reduc
exhal
nitric
oxid
signific
antiinflammatori
effect
demonstr
activ
treatment
group
rel
placebo
p
although
allerg
rhiniti
symptom
improv
significantli
follow
singl
inhal
dose
data
suggest
potenti
therapeut
role
nasal
administ
allerg
rhiniti
support
potenti
therapeut
use
allerg
inflamm
recent
report
benson
et
al
use
elisa
ultrasensit
immunoassay
investig
ascertain
rel
level
cytokin
solubl
cytokin
receptor
nasal
lavag
fluid
schoolchildren
allerg
rhiniti
pollen
season
found
level
cytokin
correl
observ
increas
eosinophil
number
ige
level
level
cytokin
addit
tumor
necrosi
factora
tnfa
ifni
illp
level
seem
correl
eosinophil
cation
protein
ecp
solubl
receptor
correl
significantli
eosinophil
solubl
receptor
ige
level
p
case
posit
correl
cytokin
solubl
receptor
could
demonstr
result
impli
releas
solubl
cytokin
receptor
occur
vivo
presenc
modulatori
effect
variou
cytokin
tomkinson
et
report
administr
murin
mutant
delet
protein
mutein
receptor
antagonist
allergen
challeng
inhibit
develop
allergenspecif
ige
respons
airway
eosinophilia
associ
increas
airway
hyperrespons
methacholin
challeng
mous
model
asthma
thu
receptor
antagon
offer
anoth
potenti
therapeut
approach
inhibit
allerg
rhiniti
reason
discuss
later
articl
see
atopi
therapi
direct
receptor
eg
mutein
monoclon
antibodi
especi
interest
agent
may
expect
inhibit
signal
induc
bind
share
receptor
subunit
anoth
characterist
cytokin
play
critic
role
eosinophil
hematopoiesi
matur
differenti
activ
loo
therefor
import
eosinophil
inflamm
asthma
allerg
diseas
hamid
et
aln
report
effort
identifi
mrna
endobronchi
mucos
biopsi
deriv
patient
asthma
n
versu
control
subject
n
mrnaposit
patient
asthma
tend
sever
diseas
base
pulmonari
function
symptom
show
greater
degre
eosinophil
activ
tlymphocyt
infiltr
bronchial
mucosa
four
mrnaneg
patient
asthma
control
subject
among
subject
posit
mrna
correl
mrna
express
number
cell
total
eosinophil
count
result
provid
earli
evid
involv
mrna
bronchial
mucosa
support
concept
cytokin
regul
eosinophil
function
asthma
allergeninduc
rhiniti
cell
seem
princip
sourc
mrna
provid
direct
evid
involv
cytokin
nasal
latephas
respons
suggest
may
appropri
antiallergi
moreov
case
product
seem
correl
asthmat
rhinit
symptom
till
et
report
tcell
product
increas
respons
antigen
stimul
atop
patient
asthma
rhiniti
asymptomat
atop
patient
nonatop
control
subject
synthesi
ige
level
could
link
tempor
symptomat
episod
allerg
rhiniti
ohashi
et
al
conclud
allergeninduc
product
appear
key
mechan
develop
symptomat
allerg
rhiniti
local
product
may
critic
eosinophil
develop
activ
local
level
appear
correl
diseas
terada
et
demonstr
actual
produc
human
nasal
mucosa
respons
antigen
challeng
use
immunohistochemistri
follow
situ
hybrid
techniqu
nasal
lavag
rhinit
subject
bronchoalveolar
lavag
bronchial
biopsi
atop
asthmat
subject
kay
et
investig
phenotyp
cell
posit
investig
found
nasal
bronchial
tissu
local
cell
remain
signal
distribut
tryptaseposit
mast
cell
subpopul
eosinophil
also
observ
nonasthmat
control
subjectspredominantli
local
cell
author
conclud
cell
princip
cellular
sourc
atop
asthma
allerg
rhiniti
subsequ
studi
investig
corrobor
find
comparison
asthmat
versu
nonasthmat
local
activ
cell
remain
signal
seen
tryptaseposit
mast
cell
activ
eosinophil
rare
detect
control
biopsi
lavag
fluid
immunohistochem
stain
inferior
turbin
biopsi
normal
versu
rhinit
subject
demonstr
stain
local
mast
cell
cell
preval
among
patient
rhiniti
stain
predominantli
associ
eosinophil
nasal
author
conclud
mast
cell
import
sourc
preform
cytokin
thu
may
contribut
chronic
mucos
inflamm
characterist
allerg
rhiniti
use
knockout
mice
aid
understand
intric
interrelationship
knockout
mice
maintain
low
level
eosinophilia
suggest
involv
factor
eosinophil
develop
granulocytemacrophag
colonystimul
factor
gmcsf
p
l
ia
e
nonetheless
mice
incap
mount
suffici
defens
helminth
infect
gener
signific
eosinophilia
respons
allergen
highaffin
receptor
gmcsf
form
cytokinespecif
chain
associ
share
common
chain
robinson
et
alsl
report
develop
eosinophil
cell
grown
gmcsf
depend
product
inhibit
partial
antibodi
coyl
et
suggest
sequenti
involv
induct
lung
mucos
immun
postul
respons
commit
naiv
cell
phenotyp
upon
activ
antigen
cell
produc
promot
eosinophil
accumul
report
publish
hamelmann
et
describ
seri
investig
conduct
use
il
defici
knockout
mice
sever
differ
mode
sensit
mous
model
allergeninduc
asthma
investig
abl
delin
distinct
role
two
cytokin
play
develop
allergeninduc
airway
inflamm
hyperrespons
confirm
import
induct
regul
allergenspecif
ige
product
enhanc
respons
addit
found
seem
critic
eosinophil
airway
infiltr
develop
airway
hyperrespons
treatment
antibodi
found
complet
inhibit
eosinophil
accumul
airway
assess
lung
digest
immunostain
therebi
prevent
develop
airway
hyperrespons
receptor
offer
potenti
target
inhibitori
therapi
asakura
et
found
mous
model
nasal
allergi
monoclon
antibodi
inhibit
antigeninduc
latephas
eosinophilia
earlyphas
nasal
symptom
tend
inhibit
histamin
hypersensit
earli
studi
monoclon
antibodi
primat
promis
danzig
review
current
state
knowledg
regard
physiolog
role
particular
attent
potenti
clinic
use
monoclon
antibodi
allerg
inflamm
conclud
use
monoclon
antibodi
approach
like
provid
proof
conceptto
show
inhibit
may
valid
target
asthma
therapi
theoret
inhibit
may
also
valid
target
treatment
allerg
rhiniti
theoret
studi
done
degre
alreadi
seen
asthma
swedish
group
employ
experiment
allergen
challeng
birch
timothi
pollen
measur
effect
topic
appli
beclomethason
versu
placebo
level
nasal
mucos
surfac
tissu
fluid
baselin
prechalleng
postchalleng
level
measur
nine
subject
allerg
rhiniti
baselin
prechalleng
level
low
patient
pretreat
corticosteroid
level
remain
low
untreat
patient
howev
demonstr
high
level
nasal
secret
allergen
challeng
author
conclud
character
latephas
nasal
reaction
allergen
even
singl
steroid
dose
attenu
respons
significantli
interestingli
gold
salt
report
effect
treatment
asthma
also
shown
inhibit
eosinophil
eosinophil
apoptosi
import
mechan
modul
allerg
inflammatori
respons
known
prolong
eosinophil
investig
surmis
gold
sodium
thiomal
gst
block
il
induc
inhibit
eosinophil
apoptosi
therebi
provid
therapeut
effect
affirm
mechan
may
studi
show
corticosteroid
treatment
asthma
exacerb
similarli
produc
eosinophil
apoptosislm
involv
molecular
cellular
interact
upregul
mhc
express
monocyt
endotheli
cell
human
lung
fibroblast
elev
level
secret
allergenspecif
cell
demonstr
bronchoalveolar
lavag
bal
fluid
atop
asthmat
nasal
mast
cell
patient
perenni
allerg
rhiniti
show
increas
express
well
ligand
fceri
rel
control
also
induc
airway
mucu
produt
differ
importantli
pertain
particularli
appar
lack
growth
factor
activ
cell
fact
express
cell
tend
occur
later
persist
longer
allergen
stimul
importantli
like
seem
capabl
induc
ig
switch
b
cell
therebi
initi
product
ige
mechan
involv
specif
proteinssign
transduc
activ
transcript
statfpres
cytoplasm
b
cell
activ
transloc
nucleu
turn
activ
gene
transcript
induc
mice
make
therebi
support
postul
si
nale
therefor
induct
critic
ige
swit
ng
eosinophilia
allerg
inflammationlm
interestingli
differenti
requir
independ
experiment
asthma
offer
altern
pathway
induct
allerg
inflammatori
featur
particularli
intrigu
context
observ
doucet
et
specif
increas
adhes
molecul
cytokin
express
human
lung
fibroblast
consequ
trigger
mainten
inflammatori
cell
recruit
home
may
help
explain
airway
remodel
therapi
target
inhibit
solubl
receptorfc
fusion
protein
develop
treatment
asthma
may
offer
futur
approach
treatment
allerg
rhiniti
inher
complex
allerg
inflamm
spark
research
mani
potenti
molecular
cellular
targetsin
mani
attempt
modul
inflamm
provid
clinic
efficaci
mani
investig
potenti
target
earli
stage
other
alreadi
clinic
trial
ige
play
key
role
allerg
inflamm
antibodi
trigger
releas
inflammatori
mediat
eg
histamin
prostaglandin
leukotrien
lead
characterist
clinic
effect
allerg
respons
antiig
bind
circul
ige
prevent
interact
ige
surfac
receptor
mast
cell
therebi
preclud
subsequ
signal
releas
mast
cell
inflammatori
mediat
antihuman
ige
antibodi
shown
promis
lower
ige
level
modul
earlyand
latephas
allerg
respons
phase
studi
atop
adult
phase
trial
allerg
rhiniti
casal
et
show
recombin
human
monoclon
antibodi
ige
significantli
decreas
serum
level
free
ige
dosedepend
manner
rhiniti
symptom
score
correl
antigenspecif
ige
level
author
conclud
monoclon
antibodi
prove
effect
therapi
allerg
diseas
unabl
demonstr
statist
clinic
signific
improv
symptom
within
dosag
rang
test
phase
trial
patient
season
allerg
rhiniti
recent
complet
although
result
yet
publish
peerreview
literatur
press
releas
state
antiig
decreas
sever
nasal
ocular
allergi
symptom
compar
placebo
reduc
number
rescu
allergi
medic
tablet
tryptas
princip
enzym
mast
cell
constitut
cellular
protein
two
form
aand
ptryptas
atryptas
produc
constitut
releas
inact
proenzym
serum
level
form
enzym
correl
mast
cell
number
ptryptas
store
secretori
granul
activ
releas
mast
cell
degranul
thu
level
ptryptas
reflect
mast
cell
activ
ptryptas
cleav
inactiv
fibrinogen
gener
enhanc
contractil
effect
histamin
smooth
muscl
stimul
prolifer
collagen
product
fibroblast
stimul
epitheli
proliferationtherebi
contribut
allerg
inflamm
inhibit
tryptas
offer
anoth
potenti
approach
therapi
tryptas
inhibitor
current
develop
use
allerg
diseasess
approach
probabl
limit
potenti
efficaci
howev
target
one
multipl
mediat
mast
cell
degranul
respons
specif
hydrolysi
camp
therefor
inhibitor
known
inhibitori
effect
bronchoconstrict
inflammatin
lo
inhibitor
believ
act
rais
intracellular
camp
context
smooth
muscl
cell
exampl
rais
intracellular
camp
level
may
lead
bronchodil
elev
camp
also
seem
inhibit
mast
cell
basophil
function
includ
mediat
product
releas
mechan
action
remain
unclear
date
mix
inhibitor
test
vitro
variou
challeng
studi
sever
anim
model
result
agent
gener
posit
measur
variou
criteria
eg
eosinophil
recruit
histamin
level
bronchoconstrict
suffici
effect
observ
warrant
investig
target
chemokin
famili
cytokin
capabl
stimul
leukocyt
motil
direct
movement
obviou
implic
allerg
inflamm
kuna
et
monitor
level
sever
factorsmonocyt
chemotact
activ
factor
monocyt
chemoattract
mcaf
mcpl
regul
activ
normal
tcell
express
secret
rant
macrophag
inflammatori
proteinla
mipla
outsid
ragwe
season
result
suggest
particip
pathogenesi
allerg
rhiniti
attract
proinflammatori
cell
subsequ
mediat
releas
import
latephas
reaction
whether
interact
might
exploit
therapeut
potenti
remain
seen
interrupt
pathway
may
impact
modul
chronic
allerg
inflamm
mention
previous
relat
adhes
receptor
particularli
play
central
role
bind
adher
vascular
transmigr
eosinophil
lymphocyt
tissu
late
activ
surfac
receptor
express
lymphocyt
cell
type
particularli
eosinophil
mast
cell
basophil
neutrophil
bind
interact
may
regul
movement
leukocyt
blood
vessel
inflammatori
site
bind
extracellular
matrix
protein
also
may
provid
costimulatori
signal
tcell
thu
inhibit
bind
would
expect
antiinflammatori
effect
nakajima
et
show
addit
effect
cell
bind
play
similar
eosinophilrecruit
roleregul
influx
cell
inflammatori
foci
involv
eosinophil
recruit
support
report
demonstr
solubl
level
correl
level
well
eosinophil
influx
bal
fluid
obtain
segment
antigen
challeng
henderson
et
al
demonstr
mous
model
asthma
blockad
one
subunit
intranas
administ
monoclon
antibodi
inhibit
sign
lung
inflamm
releas
hyperrespons
methacholin
interestingli
intraperiton
administr
monoclon
antibodi
less
effect
airway
eosinophilia
inhibit
author
postul
intrapulmonari
target
rather
circul
leukocyt
responsibleth
like
candid
lymphocyt
dendrit
cell
interstiti
macrophag
much
learn
last
decad
intric
immunolog
interrelationship
underli
allerg
inflamm
numer
clue
pathophysiolog
allerg
rhiniti
asthma
uncov
variou
potenti
therapeut
approach
begin
bear
fruit
therapi
specif
target
critic
mediat
cytokin
develop
test
hope
provid
greater
efficaci
fewer
advers
effect
proceed
excit
inquiri
cellular
molecular
constitu
doubt
emerg
potenti
target
intervent
complex
debilit
diseas
